Blockade of interleukin 1 in type 1 diabetes mellitus (Q37696271)

22 August 2017

1 reference

title

Blockade of interleukin 1 in type 1 diabetes mellitus (English)

1 reference

22 August 2017

0 references

0 references

Thomas Mandrup-Poulsen

object named as

Thomas Mandrup-Poulsen

series ordinal

1

0 references

author name string

Linda Pickersgill

series ordinal

2

1 reference

PubMed ID

20173777

22 August 2017

Marc Yves Donath

series ordinal

3

1 reference

22 August 2017

1 March 2010

1 reference

Nature Reviews Endocrinology

22 August 2017

1 reference

22 August 2017

6

1 reference

22 August 2017

158-166

1 reference

22 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1038/nrendo.2009.271

22 August 2017

0 references

cites work

IL-1 beta breaks tolerance through expansion of CD25+ effector T cells.

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

The accelerator hypothesis and increasing incidence of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Treatment of familial Mediterranean fever with anakinra.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Type 1 diabetes: recent developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

beta-Cell death during progression to diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

A choice of death--the signal-transduction of immune-mediated beta-cell apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

The c-Jun amino-terminal kinase pathway is preferentially activated by interleukin-1 and controls apoptosis in differentiating pancreatic beta-cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Monokine-producing cells predominate in the recruitment phase of NOD insulitis while cells producing Th1-type cytokines characterize the effector phase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Development of autoimmune diabetes in NOD mice is associated with the formation of peroxynitrite in pancreatic islet beta-cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Immunological and inflammatory functions of the interleukin-1 family

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

The role of interleukin-1 in disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Five-year follow-up after clinical islet transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

GAD treatment and insulin secretion in recent-onset type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Effects of insulin in relatives of patients with type 1 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Low concentration of interleukin-1beta induces FLICE-inhibitory protein-mediated beta-cell proliferation in human pancreatic islets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Endotoxin-induced hyperinsulinemia and hyperglucagonemia after experimental liver injury.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Interaction of beta-cell activity and IL-1 concentration and exposure time in isolated rat islets of Langerhans.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Interleukin-1 beta-induced stimulation of insulin release in mouse pancreatic islets is related to diacylglycerol production and protein kinase C activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

The Fas pathway is involved in pancreatic beta cell secretory function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Cytokines and beta-cell biology: from concept to clinical translation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Cytokine-induced proapoptotic gene expression in insulin-producing cells is related to rapid, sustained, and nonoscillatory nuclear factor-kappaB activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Interleukin-1beta-induced rat pancreatic islet nitric oxide synthesis requires both the p38 and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Suppressor of cytokine signaling 3 (SOCS-3) protects beta -cells against interleukin-1beta - and interferon-gamma -mediated toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Calcium has a permissive role in interleukin-1beta-induced c-jun N-terminal kinase activation in insulin-secreting cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Nitric oxide contributes to cytokine-induced apoptosis in pancreatic beta cells via potentiation of JNK activity and inhibition of Akt.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Cytokines downregulate the sarcoendoplasmic reticulum pump Ca2+ ATPase 2b and deplete endoplasmic reticulum Ca2+, leading to induction of endoplasmic reticulum stress in pancreatic beta-cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Transfection of human pancreatic islets with an anti-apoptotic gene (bcl-2) protects beta-cells from cytokine-induced destruction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Proapoptotic BH3-only protein Bid is essential for death receptor-induced apoptosis of pancreatic beta-cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Proinflammatory cytokines activate the intrinsic apoptotic pathway in beta-cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Endoplasmic reticulum stress-mediated apoptosis in pancreatic beta-cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Cytokine-induced beta-cell death is independent of endoplasmic reticulum stress signaling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

The BCL-2 protein family: opposing activities that mediate cell death

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Bax and Bak can localize to the endoplasmic reticulum to initiate apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Cytokine-induced apoptosis and necrosis are preceded by disruption of the mitochondrial membrane potential (Deltapsi(m)) in pancreatic RINm5F cells: prevention by Bcl-2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Bad news for beta-cell apoptosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Protection from experimental autoimmune diabetes in the non-obese diabetic mouse with soluble interleukin-1 receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

IL-1 receptor deficiency slows progression to diabetes in the NOD mouse

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Caspase-1 is not required for type 1 diabetes in the NOD mouse

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Changing Prevalence of Overweight Children and Adolescents at Onset of Insulin-Treated Diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Monokine Antagonism Is Reduced in Patients With IDDM

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Association of immune mediators at diagnosis of Type 1 diabetes with later clinical remission

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Use of canakinumab in the cryopyrin-associated periodic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Rapid responses to anakinra in patients with refractory adult-onset Still's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Islet inflammation in type 2 diabetes: from metabolic stress to therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Interleukin-1-receptor antagonist in type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

A pilot study of IL-1 inhibition by anakinra in acute gout

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Anakinra for flares of pyogenic arthritis in PAPA syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Successful treatment of resistant pseudogout with anakinra

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Beneficial response to anakinra and thalidomide in Schnitzler's syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.271

Human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic beta-cell cytotoxicity

31 March 2020

1 reference

12 December 2020

IL-1 receptor antagonism and muscle gene expression in patients with type 2 diabetes.

1 reference

12 December 2020

The role of interleukin-1 in the pathogenesis of IDDM.

1 reference

12 December 2020

Biologic basis for interleukin-1 in disease

1 reference

12 December 2020

Coupling endoplasmic reticulum stress to cell death program in isolated human pancreatic islets: effects of gene transfer of Bcl-2.

1 reference

12 December 2020

Biology of interleukin 1.

1 reference

12 December 2020

Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. The Canadian-European Randomized Control Trial Group

1 reference

12 December 2020

Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2009.271

1 reference

22 August 2017

1 reference

PubMed ID

20173777